IMP-32

N/A

Report date: 2026/04/20 20:01:59
First In Class

Base Information

Drug NameIMP-32
Drug Alias NameIMP32IMP-32
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA topoisomerase I inhibitorsSerine-protein kinase ATR inhibitorsAnti-CEACAM5
TargetsDNA topoisomerase ISerine-protein kinase ATRCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesImpact Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A